Denosumab is an anti-bone resorptive drug consisting of complete human monoclonal antibodies that targets receptor activator of nuclear factor B ligand (RANKL), which is responsible for osteoclast formation. The drug has been adapted for bone diseases, such as osteoporosis and bone metastasis related to cancer, but is not used for alveolar bone destruction related to periodontitis. In the present study, we aimed to clarify whether denosumab prevents bone destruction associated with lipopolysaccharide (LPS)-induced calvaria inflammation and experimental periodontitis in model mice. Denosumab does not bind to mouse RANKL, thus we used anti-mouse monoclonal RANKL antibodies. We also examined the inhibitory effects toward bone destruction of another anti-bone resorptive drug zoledronate, a nitrogen-containing bisphosphonate. Local administration of anti-RANKL antibodies into the calvaria area inhibited LPS-induced osteoclast formation and bone destruction, while zoledronate inhibited bone destruction but not osteoclast formation due to its different action mechanism. In periodontitis model mice, in which the second molars were ligated with a silk suture to induce inflammation, intraperitoneal administration of anti-RANKL antibodies significantly inhibited alveolar bone destruction and tooth root exposure. On the other hand, zoledronate only weakly repressed alveolar bone destruction and failed to inhibit root exposure. These results suggest that denosumab is a promising candidate to prevent alveolar bone destruction associated with periodontitis. Fig. 1 ).
periodontitis model was somehow different from that of osteoporosis, thus resulting in our findings regarding the action of zoledronate.
2) How do you think possible side effects of Denosumab? For example, whether its local administration can affect on other bones? Systematic administration with an intraperitoneal injection of zoledronate as well as that with anti-RANKL antibodies significantly increased bone mass in the femurs of the periodontitis model mice, whereas local injection to calvaria did not have such effects (Supplementary Fig. 1 ).
In response to questions 1) and 2) above, we have added the following to the Discussion section of the revised manuscript. "The reason why zoledronate did not inhibit alveolar bone as well as the anti-mouse RANKL antibodies is not clear. We speculate that the microenvironmental condition of alveolar bone destruction in periodontitis model mice was somehow different as compared to that of osteoporosis, thus resulting in our findings for the action of zoledronate. Systematic administration with intraperitoneal injection of zoledronate or anti-RANKL antibodies significantly increased femur bone mass in the periodontitis model, whereas neither given as a local injection showed such an effect ( Supplementary Fig. 1 ). Pharmacokinetic monitoring of bones and femurs affected by periodontitis for comparisons of zoledronate and anti-RANKL antibodies is necessary to reveal the different action mechanisms of these drugs."
3) I couldn't find the description about the administration procedure of anti-mouse monoclonal RANKL antibodies in experimental periodontitis. Please indicate it in the materials and methods section. We apologize that the procedure for administration of the drugs in the periodontitis model mice was not described in the original version of the text. In the revised version, we have modified that portion to provide a description of the procedure used, as follows. "Under anesthesia with isoflurane inhalation, the cervix of the maxillary left second molar in mice was ligated with a silk suture (size 5-0, MATSUDAIKA KOGYO Co., Ltd., Tokyo, Japan) 14) , then an intraperitoneal administration of saline (200 µl), anti-RANKL antibodies (3 mg/kg), or zoledronate (0.2 mg/kg) was given. At 0, 1, and 2 weeks after ligation and drug administration, each mouse head was subjected to µCT scanning under anesthesia." 4) How do you think whether Denosumab can be effective if administration of Denosumab starts after partial development of periodontitis? Please indicate your thoughts in the discussion section. As suggested by the reviewer, we agree that it is important to use denosumab for periodontitis treatment. We think that an administration of anti-RANKL antibodies interrupts the progress of alveolar bone destruction. However, whether alveolar bone volume increases as a result or not is unclear. Regarding the reviewer's question, we have added the following to the revised Discussion section. "The present study shows results of pre-treatment with anti-RANKL antibodies in periodontitis model mice, whereas post-treatment effects were not examined. We speculate that anti-RANKL antibodies interrupt destruction and stop the decrease in alveolar bone volume. On the other hand, a dramatic increase in alveolar bone volume is not anticipated when the regenerative potency of alveolar bone is reduced in patients. Additional analyses are necessary to reveal the precise effects of denosumab on periodontal bone disease." (ii) Anonymized information unable to track its resource.
(iii) The anonymization processing or deidentification processing of personal information that has been already made.
[ to inhibit root exposure. These results suggest that denosumab is a promising candidate to prevent alveolar bone destruction associated with periodontitis.
Key words
denosumab, periodontitis, bone, osteoclast, molecularly targeted drug, bisphosphonate
INTRODUCTION
Denosumab is a powerful anti-bone resorptive drug produced for treatment of osteoporosis patients who have a high risk for fracture, as well as development of cancer metastasis and giant cell tumors in bone tissue 1) . The drug consists of human monoclonal antibodies that bind to receptor activator of nuclear factor B ligand (RANKL), a tumor necrosis factor (TNF)-super family cytokine produced by osteoblasts and stromal cells in bone tissues 2) . RANKL plays roles in signal transduction for osteoclast differentiation and function by binding to its receptor RANK (receptor activator of nuclear factor B) expressed on mature osteoclasts and their precursors [3] [4] [5] . Thus, denosumab inhibits bone destruction caused by enhanced differentiation and function of osteoclasts by interrupting RANKL and RANK interactions.
Destruction of alveolar bone occurs in patients with severe periodontitis, which is characterized by chronic gingival inflammation 6) . Dental plaque, which contains bacterial constituents such as lipopolysaccharide (LPS), stimulates osteoclast differentiation via production of inflammatory factors including interleukin (IL)-1, TNF- and prostaglandins (PGs) 7) . These factors enhance differentiation of osteoclasts on alveolar bone in both direct and indirect manners, resulting in tooth loss due to alveolar bone destruction 6) .
Regular brushing is known to be the most effective means of keeping the periodontal area clean and preventing periodontitis 8) . However, handicapped or bedridden individuals find it difficult to use a dental brush by themselves, and tend to have severe periodontitis, leading to tooth loss. Therefore, establishment of alternative methods for prevention of alveolar bone destruction accompanied by periodontitis is very important. One possible method is local administration of an anti-bone resorptive drug such as denosumab in alveolar bone areas. However, it is not known if that drug is effective for treatment and prevention of alveolar bone destruction caused by periodontitis.
In the present study, to clarify whether drug therapy using denosumab can prevent bone destruction in association with periodontitis, we examined the effects of anti-mouse RANKL monoclonal antibodies, used to mimic denosumab, on LPS-induced calvarial bone destruction and alveolar bone destruction related to periodontitis induced experimentally in mice. In addition, we examined the effects of the bisphosphonate zoledronate, another type of anti-bone resorptive drug, and compared them with those of the anti-mouse RANKL monoclonal antibodies in mouse models of bone destruction.
Our results showed that administration of anti-mouse RANKL monoclonal antibodies strongly inhibited calvarial and alveolar bone destruction, suggesting that denosumab may be a good candidate drug for treatment of periodontitis-induced alveolar bone destruction. 
MATERIALS AND METHODS

Reagents
Animals and ethical approval
Eight-week-old C57BL/6j male mice were purchased from Sankyo Labo Service Corporation, Inc. (Tokyo, Japan). All animal experiments were approved by the Showa University Animal Care and Use Committee (approval number: 17041), and conducted according to the ethical guidelines of that institution.
LPS-induced calvarial bone destruction model mice
Mice were anesthetized with isoflurane inhalation, then collagen gel (200 µl)
containing LPS (25 mg/kg) with or without anti-RANKL antibodies (3 mg/kg), zoledronate (0.2 mg/kg), or saline (control) was injected into the vertex of the head.
After 5 days, calvarial portions were excised and fixed in 70% ethanol for 1 hour.
Subsequently, the specimens were examined using micro-computed tomography (µCT)
to analyze calvarial structures as well as histomorphological analysis to detect osteoclasts 9) . The most effective dosages of LPS, anti-RANKL antibodies, and zoledronate administered to the mice were selected on the basis of previously reported findings [10] [11] [12] .
Detection of osteoclasts in calvaria
Calvarial specimens excised from mice were fixed in 70% ethanol for tartrate-resistant acid phosphatase (TRAP; a marker of osteoclasts) staining using a conventional method with Naphtol AS-MX phosphate (Sigma-Aldrich) and Fast red (Sigma-Aldrich) dissolved in 0.1 M acetic buffer (pH 5.0) containing 1% tartrate acid (Wako Pure Chemical Industries, Ltd., Tokyo, Japan) 13) . Fixed specimens were embedded in O.C.T. compound (Sakura Finetek Japan Co., Ltd., Tokyo, Japan) and cut into coronal sections, which were stained for TRAP 13) .
Experimental periodontitis model
Under anesthesia with isoflurane inhalation, the cervix of the maxillary left second molar in mice was ligated with a silk suture (size 5-0, MATSUDAIKA KOGYO Co., Ltd., Tokyo, Japan) 14) , then an intraperitoneal administration of saline (200 µl),
anti-RANKL antibodies (3 mg/kg), or zoledronate (0.2 mg/kg) was given. At 0, 1, and 2
weeks after ligation and drug administration, each mouse head was subjected to µCT scanning under anesthesia. The ligatures in all mice remained in place throughout the experimental period. The exposed length of the tooth root was calculated by comparing µCT images obtained at 0 and 2 weeks.
µCT analysis
Three-dimensional digital images of the calvaria in LPS-induced bone destruction model mice were reconstructed from µCT analysis findings using a ScanXmate-L090H
(Comscantecno, Co., Ltd., Yokohama, Japan). Histomorphological analysis of the µCT images was performed using a TRI/3D-Bon ® system (RATOC System Engineering Co., Ltd. Tokyo, Japan). Three-dimensional digital images of alveolar bones and teeth in periodontitis model mice were reconstructed from µCT analysis findings using an in vivo 3D µCT system (R_mCT2, Rigaku Co., Ltd., Tokyo, Japan).
Statistical analysis
Statistical analyses were performed using the IBM PASW ® statistical software package, version 18.0 (IBM, Chicago IL, USA). Values are presented as the mean ± SD.
A p value <0.05 was considered to be significant. For experiments involving 6 factors, data were analyzed using one-way ANOVA or Student's t-test.
RESULTS
Administration of anti-mouse RANKL antibodies but not zoledronate inhibits osteoclast formation induced by LPS in calvaria
Denosumab does not bind to mouse RANKL, thus we used anti-mouse RANKL antibodies in this study. Initially, we examined the effects of anti-mouse RANKL antibodies on LPS-induced osteoclast formation in calvarial specimens. Following injection of LPS with saline, an increase in size of TRAP-positive areas, indicating osteoclast formation, was found along calvaria sutures as compared to the control mice (Fig. 1A, 1B , left upper and lower panels). In contrast, simultaneous injection with anti-mouse RANKL antibodies resulted in dramatically smaller TRAP-positive areas induced by LPS (Fig. 1A, 1B , lower middle panels). In addition, administration of anti-mouse RANKL antibodies reduced the size of the primary TRAP-positive areas in the control mice (Fig. 1A, 1B , upper middle panels). On the other hand, zoledronate failed to inhibit the increase in size of TRAP-positive areas in the LPS-injected and control mice (Fig. 1A, 1B , right upper and lower panels). These results indicate that anti-mouse RANKL antibodies inhibit osteoclast formation induced by LPS in the calvaria, while zoledronate does not have such an effect.
Anti-mouse RANKL antibodies and zoledronate inhibit bone resorption induced by LPS in calvaria
Next, we examined the effects of anti-mouse RANKL antibodies and zoledronate on calvarial bone destruction induced by LPS ( Fig. 2A, B, C) . The square in Figure 2A encloses the portion of the calvaria where the number of resorption pits formed by osteoclasts was counted. The number of resorption pits in LPS-injected mice was significantly increased ( These results indicate that both anti-mouse RANKL antibodies and zoledronate inhibit calvarial bone destruction induced by LPS.
Anti-mouse RANKL antibodies inhibit alveolar bone destruction more effectively than zoledronate in periodontitis model mice
To examine the effects of anti-mouse RANKL antibodies and zoledronate on alveolar bone destruction caused by periodontitis, we performed intraperitoneal administrations of those agents in mice following ligation of the upper-right second molar with a silk suture to induce periodontal inflammation (Fig. 3A, B, C) . Figure 3B shows representative CT images of upper jaws of periodontitis model mice at 0, 1, and 2 weeks after silk suture ligation of the right molars. After 1 and 2 weeks, apparent loss of alveolar bone was observed around the right but not the left molars in the control mice, which had received an injection of saline (Fig. 3B, left lane panels, 3C ). On the other hand, alveolar bone loss in mice that received an injection of anti-mouse RANKL antibodies was significantly inhibited (Fig. 3B, middle lane panels, 3C ). In the zoledronate-injected mice, partial inhibition of alveolar bone loss was observed (Fig. 3B , right lane panels, 3C). 
DISCUSSION
Application of minocycline, an antimicrobial drug, to periodontal pockets is generally performed to treat periodontitis 15) . However, such antimicrobial agents do not show inhibitory effects toward alveolar bone destruction in patients with severe periodontitis. Thus, novel drugs to prevent alveolar bone destruction related to periodontitis are anticipated. In the present study, we found that administration of anti-RANKL antibodies strongly suppressed calvarial bone destruction induced by LPS and alveolar bone destruction associated with periodontitis in model mice. Our results suggest that denosumab would be applicable for prevention of alveolar bone destruction seen in periodontitis patients.
LPS, a major constituent of bacteria, induces inflammatory cytokines and prostaglandins via Toll-like receptors, and those inflammatory factors have been suggested to induce alveolar bone destruction associated with periodontitis by enhancing osteoclast differentiation 16)17) . In the present LPS-induced calvarial bone destruction model, local administration of anti-mouse RANKL antibodies into the calvaria region reduced the number of osteoclasts and suppressed resorption pit formation, indicating that even though production of inflammatory factors was induced by LPS, RANKL signaling is essential to induce osteoclast formation. In contrast, zoledronate failed to reduce the number of osteoclasts induced by LPS, suggesting that its action is independent of RANKL signaling. Weinstein et al 18) . reported that the number of giant osteoclasts without bone resorption activity was increased in Note that local administration of anti-mouse RANKL antibodies or zoledronate did
